Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385688052> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4385688052 endingPage "245.13" @default.
- W4385688052 startingPage "245.13" @default.
- W4385688052 abstract "Abstract Although the incidence of conjunctival melanoma is rare, it is a highly metastatic tumor with high recurrence and mortality rates. The current conjunctival melanoma treatment strategies, including surgical resection combined with chemo- or cryotherapy, have limited usefulness because of systemic side effects, recurrence, and metastases. Tumor-intrinsic Wnt/β-catenin pathway mediates immune exclusion in the tumor microenvironment (TME) and promotes tumorigenesis. Previous studies have shown that XAV939, a potent tankyrase inhibitor, can be used for the pharmacological inhibition of β-catenin. In this study, using tocopheryl polyethylene glycol 1000 succinate (TPGS)-based nanoparticle formulation for XAV939, we show that β-catenin inhibition suppresses melanoma cell proliferation and migration. Additionally, XAV939 nanoparticles promoted immunogenic cell death (ICD) of tumor cells with a significant extracellular release of ICD molecules, including HMGB1, calreticulin, and ATP. Further, using a mouse model of conjunctival melanoma, we show that β-catenin inhibition significantly suppresses conjunctival melanoma progression. Collectively, the local delivery of β-catenin represents a novel and safe approach to promoting ICD and activating anti-tumor immunity for combinatorial immune checkpoint inhibition therapies against vision and life-threatening ocular melanomas. This study was supported by research funding from the Intramural Grants Program, Auburn University Research Initiative in Cancer (AURIC), and start-up funds from the Department of Pathobiology, College of Veterinary Medicine, Auburn University." @default.
- W4385688052 created "2023-08-10" @default.
- W4385688052 creator A5000093173 @default.
- W4385688052 creator A5034077901 @default.
- W4385688052 creator A5040708860 @default.
- W4385688052 creator A5042209857 @default.
- W4385688052 creator A5042739072 @default.
- W4385688052 date "2023-05-01" @default.
- W4385688052 modified "2023-09-27" @default.
- W4385688052 title "β-catenin inhibition using XAV939 nanoparticle promotes immunogenic cell death and suppresses tumor progression" @default.
- W4385688052 doi "https://doi.org/10.4049/jimmunol.210.supp.245.13" @default.
- W4385688052 hasPublicationYear "2023" @default.
- W4385688052 type Work @default.
- W4385688052 citedByCount "0" @default.
- W4385688052 crossrefType "journal-article" @default.
- W4385688052 hasAuthorship W4385688052A5000093173 @default.
- W4385688052 hasAuthorship W4385688052A5034077901 @default.
- W4385688052 hasAuthorship W4385688052A5040708860 @default.
- W4385688052 hasAuthorship W4385688052A5042209857 @default.
- W4385688052 hasAuthorship W4385688052A5042739072 @default.
- W4385688052 hasBestOaLocation W43856880521 @default.
- W4385688052 hasConcept C121608353 @default.
- W4385688052 hasConcept C126322002 @default.
- W4385688052 hasConcept C137620995 @default.
- W4385688052 hasConcept C203014093 @default.
- W4385688052 hasConcept C2776107976 @default.
- W4385688052 hasConcept C2777658100 @default.
- W4385688052 hasConcept C2777701055 @default.
- W4385688052 hasConcept C2777877232 @default.
- W4385688052 hasConcept C2779256057 @default.
- W4385688052 hasConcept C30145163 @default.
- W4385688052 hasConcept C3020616263 @default.
- W4385688052 hasConcept C502942594 @default.
- W4385688052 hasConcept C62478195 @default.
- W4385688052 hasConcept C71924100 @default.
- W4385688052 hasConcept C86803240 @default.
- W4385688052 hasConcept C8891405 @default.
- W4385688052 hasConcept C95444343 @default.
- W4385688052 hasConceptScore W4385688052C121608353 @default.
- W4385688052 hasConceptScore W4385688052C126322002 @default.
- W4385688052 hasConceptScore W4385688052C137620995 @default.
- W4385688052 hasConceptScore W4385688052C203014093 @default.
- W4385688052 hasConceptScore W4385688052C2776107976 @default.
- W4385688052 hasConceptScore W4385688052C2777658100 @default.
- W4385688052 hasConceptScore W4385688052C2777701055 @default.
- W4385688052 hasConceptScore W4385688052C2777877232 @default.
- W4385688052 hasConceptScore W4385688052C2779256057 @default.
- W4385688052 hasConceptScore W4385688052C30145163 @default.
- W4385688052 hasConceptScore W4385688052C3020616263 @default.
- W4385688052 hasConceptScore W4385688052C502942594 @default.
- W4385688052 hasConceptScore W4385688052C62478195 @default.
- W4385688052 hasConceptScore W4385688052C71924100 @default.
- W4385688052 hasConceptScore W4385688052C86803240 @default.
- W4385688052 hasConceptScore W4385688052C8891405 @default.
- W4385688052 hasConceptScore W4385688052C95444343 @default.
- W4385688052 hasIssue "1_Supplement" @default.
- W4385688052 hasLocation W43856880521 @default.
- W4385688052 hasOpenAccess W4385688052 @default.
- W4385688052 hasPrimaryLocation W43856880521 @default.
- W4385688052 hasRelatedWork W2810269284 @default.
- W4385688052 hasRelatedWork W2901247462 @default.
- W4385688052 hasRelatedWork W2944928637 @default.
- W4385688052 hasRelatedWork W3093473476 @default.
- W4385688052 hasRelatedWork W3212686885 @default.
- W4385688052 hasRelatedWork W4206018902 @default.
- W4385688052 hasRelatedWork W4210390972 @default.
- W4385688052 hasRelatedWork W4304979265 @default.
- W4385688052 hasRelatedWork W4309003743 @default.
- W4385688052 hasRelatedWork W4313395918 @default.
- W4385688052 hasVolume "210" @default.
- W4385688052 isParatext "false" @default.
- W4385688052 isRetracted "false" @default.
- W4385688052 workType "article" @default.